JAK Inhibitor Benefits in Type 1 Diabetes Lost After Discontinuation

By News Health
3 weeks Ago

(MedPage Today) — The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed.
After treatment was stopped, C-peptide…

Source link : https://www.medpagetoday.com/meetingcoverage/easd/117538

Author :

Publish date : 2025-09-18 22:01:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

GLP 1s and Libido: An Effect That May Fly Under the Radar

Starving Children Screaming for Food as U.S. Aid Cuts Unleash Devastation and Death

Could Oral Microbiome Test Indicate Pancreatic Cancer Risk?

Trump Administration Begins Firing Federal Health Workers Amid Shutdown

Here's How Much Medicaid Spends on Undocumented Immigrants

GPs Split on PSA Testing as Clearer Guidance Urged